Regulation of Kv4 channel expression in failing rat heart by the thioredoxin system.
Redox imbalance elicited by oxidative stress contributes to pathogenic remodeling of ion channels that underlies arrhythmogenesis and contractile dysfunction in the failing heart. This study examined whether the expression of K(+) channels in the remodeled ventricle is controlled by the thioredoxin system, a principal oxidoreductase network regulating redox-sensitive proteins. Ventricular dysfunction was induced in rats by coronary artery ligation, and experiments were conducted 6-8 wk postinfarction. Biochemical assays of tissue extracts from infarcted hearts showed that thioredoxin reductase activity was decreased by 32% from sham-operated controls (P < 0.05), whereas thioredoxin activity was 51% higher postinfarction (P < 0.05). These differences in activities paralleled changes in protein abundance as determined by Western blot analysis. However, whereas real-time PCR showed thioredoxin reductase mRNA levels to be significantly decreased postinfarction, thioredoxin mRNA was not altered. In voltage-clamp studies of myocytes from infarcted hearts, the characteristic downregulation of transient-outward K(+) current density was reversed by exogenous pyruvate (5 mmol/l), and this effect was blocked by the specific inhibitors of the thioredoxin system: auranofin or 13-cis-retinoic acid. Real-time PCR and Western blot analyses of myocyte suspensions from infarcted hearts showed that pyruvate increased mRNA and protein abundance of Kv4.2 and Kv4.3 channel alpha-subunits as well as the accessory protein KChIP2 when compared with time-matched, untreated cells (P < 0.05). The pyruvate-induced increase in Kv4.x expression was blocked by auranofin, but the upregulation of KChIP2 expression was not affected. These data suggest that the expression of Kv4.x channels is redox-regulated by the thioredoxin system, which may be a novel therapeutic target to reverse or limit electrical remodeling of the failing heart.
Dept. of Cellular and Integrative Physiology, Univ. of Nebraska Medical Ctr., Omaha, NE 68198-5850, USA.
Xun
X
Li
Kang
K
Tang
Bin
B
Xie
Shumin
S
Li
George J
GJ
Rozanski
D000818:Animals; D001310:Auranofin / Q000494:pharmacology; D015153:Blotting, Western; D004195:Disease Models, Animal; D006333:Heart Failure / Q000209:etiology / Q000378:metabolism* / Q000503:physiopathology; D015474:Isotretinoin / Q000494:pharmacology; D051605:Kv Channel-Interacting Proteins / Q000378:metabolism; D008297:Male; D008564:Membrane Potentials; D009203:Myocardial Infarction / Q000150:complications* / Q000378:metabolism / Q000503:physiopathology; D009206:Myocardium / Q000201:enzymology / Q000378:metabolism*; D010084:Oxidation-Reduction; D018384:Oxidative Stress; D018408:Patch-Clamp Techniques; D011188:Potassium / Q000378:metabolism*; D019289:Pyruvic Acid / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D020133:Reverse Transcriptase Polymerase Chain Reaction; D051672:Shal Potassium Channels / Q000235:genetics / Q000378:metabolism*; D013880:Thioredoxin-Disulfide Reductase / Q000378:metabolism; D013879:Thioredoxins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D020257:Ventricular Remodeling
C496758:Kcnip2 protein, rat; D051605:Kv Channel-Interacting Proteins; D051672:Shal Potassium Channels; D001310:Auranofin; D013879:Thioredoxins; D019289:Pyruvic Acid; D013880:Thioredoxin-Disulfide Reductase; D015474:Isotretinoin; D011188:Potassium